Trial reportNutrients2020
Effects on Gastroesophageal Reflux of Donkey Milk-Derived Human Milk Fortifier Versus Standard Fortifier in Preterm Newborns: Additional Data from the FortiLat Study.
Trial report in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Efficacy and safety of non-pharmacological interventions for gastroesophageal reflux and gastroesophageal reflux disease in children: a systematic review.Italian journal of pediatrics · 2026Pooled it
- Guidelines on diagnosis and management of gastroesophageal reflux disease in infants, children and adolescents: a joint consensus from Italian pediatric societies (SIP and SIGENP) -Part II: management.Italian journal of pediatrics · 2026Guideline
- Impact of three mammalian milk-derived fortifiers on morbidity and mortality in preterm infants: a systematic review and network meta-analysis.International breastfeeding journal · 2025Pooled it
- The "Fortilat" Randomized Clinical Trial Follow-Up: Neurodevelopmental Outcome at 18 Months of Age.Nutrients · 2020Trial
- The "Fortilat" Randomized Clinical Trial Follow-Up: Auxological Outcome at 18 Months of Age.Nutrients · 2020Trial
- Urinary Metabolomic Profile of Preterm Infants Receiving Human Milk with Either Bovine or Donkey Milk-Based Fortifiers.Nutrients · 2020Trial
- Potential Anticancer Activity of Donkey Milk in Human Gastric Adenocarcinoma (AGS) Cell Line.Biology · 2026Article
- Narrative review of human milk fortifiers for preterm infants.Frontiers in pediatrics · 2026Review
- Machine learning prediction of feeding intolerance in preterm infants: a pre-feeding risk stratification model.Frontiers in pediatrics · 2025Article
- Strategies for the Fortification of Human Milk in Preterm Infants: A Systematic Review.Cureus · 2024Review
- Effects of Methionine on Milk Performance and Milk Constituents of Lactating Donkeys.Animals : an open access journal from MDPI · 2024Article
- Pediatric Laryngopharyngeal Reflux: An Evidence-Based Review.Children (Basel, Switzerland) · 2023Review
- Valorization of donkey milk: Technology, functionality, and future prospects.JDS communications · 2022Review
- The Donkey Milk in Infant Nutrition.Nutrients · 2022Article
- Current Knowledge on Functionality and Potential Therapeutic Uses of Donkey Milk.Animals : an open access journal from MDPI · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFeeding intolerance is a frequent diagnosis in very preterm infants. As seen in the FortiLat trial, human milk fortification with the new donkey milk-derived human milk fortifier (DF) seems to improve feeding tolerance in these infants. The aim of this study was to evaluate the effects of using the DF compared with bovine milk-derived fortifier (BF) on gastroesophageal reflux (GER) in very low birth weight (VLBW) infants.
methodsOver a total of 156 preterm infants were enrolled into the FortiLat trial (GA <32 weeks and birth weight <1500 g) and randomized into the BF arm or DF arm, and we selected all infants with clinical signs of GER and cardiorespiratory (CR) symptoms. All the infants underwent CR and multichannel intraluminal impedance and pH (MII/pH) monitoring associated with gastric ultrasound to evaluate GER and gastric emptying time.
results10 infants were enrolled, and 5 were in the DF arm. At MII/pH, infants enrolled into the DF arm showed a lower GER frequency than BF arm infants (
conclusionThe use of donkey-derived human milk fortifier reduced the GER frequency and consequently should be recommended in infants with feeding intolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.